Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma
Dickran Kazandjian(United States Food and Drug Administration), Jennifer Jones(Dalhousie University), Barış Türkbey(National Institutes of Health), Joseph Roswarski(Georgetown University), Kevin Camphausen(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), Katherine R. Calvo(National Institutes of Health Clinical Center), Alexander Dew(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Elizabeth Gil Ramirez(National Institutes of Health), Raul C. Braylan(Center for Cancer Research), Esther Mena(National Institutes of Health), William D. Figg(National Cancer Institute), Liza Lindenberg(National Cancer Institute), Peter L. Choyke(National Cancer Institute), Hao‐Wei Wang(Fu Jen Catholic University), Elizabeth Hill(University of Maryland, Baltimore), Irina Marić(Center for Cancer Research), Michael Emanuel(National Institutes of Health), Alina Dulau‐Florea(National Institutes of Health), Candis Morrison(National Institutes of Health), Constance M. Yuan(National Cancer Institute)
Cited by 26
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817